Versant Capital Management, Inc Denali Therapeutics Inc. Transaction History
Versant Capital Management, Inc
- $431 Million
- Q3 2024
A detailed history of Versant Capital Management, Inc transactions in Denali Therapeutics Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 203 shares of DNLI stock, worth $5,450. This represents 0.0% of its overall portfolio holdings.
Number of Shares
203
Previous 101
100.99%
Holding current value
$5,450
Previous $2,000
150.0%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding DNLI
# of Institutions
216Shares Held
115MCall Options Held
127KPut Options Held
38.3K-
Baillie Gifford & CO13.8MShares$370 Million0.25% of portfolio
-
Black Rock Inc. New York, NY13.2MShares$354 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA11.3MShares$304 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA9.82MShares$264 Million0.04% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.13MShares$191 Million0.04% of portfolio
About Denali Therapeutics Inc.
- Ticker DNLI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 134,174,000
- Market Cap $3.6B
- Description
- Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...